Atrial fibrillation-induced tachycardiomyopathy and heart failure: an underappreciated and elusive condition

被引:0
|
作者
Antonis S. Manolis
Theodora A. Manolis
Antonis A. Manolis
Helen Melita
机构
[1] Athens University School of Medicine,First Department of Cardiology
[2] Aghia Sofia University Hospital,undefined
[3] Patras University School of Medicine,undefined
[4] Onassis Cardiac Surgery Center,undefined
来源
Heart Failure Reviews | 2022年 / 27卷
关键词
Atrial fibrillation; Tachycardiomyopathy; Heart failure; Left ventricular dysfunction; Ablation;
D O I
暂无
中图分类号
学科分类号
摘要
Many patients with persistent, chronic, or frequently recurring paroxysmal atrial fibrillation (AF) may develop a tachycardiomyopathy (TCM) with left ventricular (LV) dysfunction and heart failure (HF), which is reversible upon restoration and maintenance of sinus rhythm, when feasible, or via better and tighter ventricular rate (VR) control. Mechanisms involved in producing this leading cause of TCM (AF-TCM) include loss of atrial contraction, irregular heart rate, fast VR, neurohumoral activation, and structural myocardial changes. The most important of all mechanisms relates to optimal VR control, which seems to be an elusive target. Uncontrolled AF may also worsen preexisting LV dysfunction and exacerbate HF symptoms. Data, albeit less robust, also point to deleterious effects of slow VRs on LV function. Thus, a J-shaped relationship between VR and clinical outcome has been suggested, with the optimal VR control hovering at ~ 65 bpm, ranging between 60 and 80 bpm; VRs above and below this range may confer higher morbidity and mortality rates. A convergence of recent guidelines is noted towards a stricter rather than a more lenient VR control with target heart rate < 80 bpm at rest and < 110 bpm during moderate exercise which seems to prevent TCM or improve LV function and exercise capacity and relieve TCM-related symptoms and signs. Of course, restoring and maintaining sinus rhythm is always a most desirable target, when feasible, either with drugs or more likely with ablation. All these issues are herein reviewed, current guidelines are discussed and relevant data are tabulated and pictorially illustrated.
引用
收藏
页码:2119 / 2135
页数:16
相关论文
共 50 条
  • [31] Heart failure and atrial fibrillation
    Otilia Tica, O. A.
    Tica, O.
    Rosan, L.
    Popescu, M. I.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 99 - 99
  • [32] Heart failure and atrial fibrillation
    Roubin, Sergio Raposeiras
    Canoa, Nicolas Lopez
    MEDICINA CLINICA, 2024, 163 (11): : 568 - 569
  • [33] Heart Failure and Atrial Fibrillation
    McCulloch, Brenda
    CRITICAL CARE NURSING CLINICS OF NORTH AMERICA, 2015, 27 (04) : 427 - +
  • [34] Atrial fibrillation and heart failure
    Bergau, Leonard
    INNERE MEDIZIN, 2024, 65 (08): : 755 - 761
  • [35] HEART FAILURE AND ATRIAL FIBRILLATION
    Musa, F.
    Shahzad, A.
    Engel, L. S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2010, 58 (02) : 376 - 376
  • [36] Atrial fibrillation and heart failure
    Santini, M
    Ricci, R
    EUROPACE, 2004, 5 : S55 - S59
  • [37] Atrial fibrillation in heart failure
    Stevenson, WG
    Stevenson, LW
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (12): : 910 - 911
  • [38] Atrial Fibrillation in Heart Failure
    Lardizabal, Joel A.
    Deedwania, Prakash C.
    MEDICAL CLINICS OF NORTH AMERICA, 2012, 96 (05) : 987 - +
  • [39] Atrial Fibrillation and Heart Failure
    Marzlin, Karen M.
    AACN ADVANCED CRITICAL CARE, 2020, 31 (04) : 431 - 434
  • [40] Atrial Fibrillation and Heart Failure
    Bergau, Leonard
    Bengel, Philipp
    Sciacca, Vanessa
    Fink, Thomas
    Sohns, Christian
    Sommer, Philipp
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (09)